2026年8月19日，国药控股股份有限公司（01099）公告了其附属公司国药集团药业股份有限公司（国药股份，A股代码：600511）截至2026年6月30日止六个月的主要未经审计财务数据。公告要点如下：
1. 资产情况 截至报告期末，国药股份总资产为360.40亿元，较上年度末的366.85亿元下降1.76%；归属于上市公司股东的净资产为188.10亿元，较上年度末的185.45亿元增长1.43%。
2. 经营业绩 报告期内，公司实现营业收入267.28亿元，同比增长4.27%；利润总额11.43亿元，同比下降6.83%；归属于上市公司股东的净利润8.80亿元，同比下降7.25%。扣除非经常性损益后，归属于上市公司股东的净利润为8.80亿元，同比下降5.55%。
3. 现金流与收益指标 报告期经营活动产生的现金流量净额为-26.34亿元，上年同期为-15.10亿元。基本及稀释每股收益均为1.1660元，同比下降7.25%。期内加权平均净资产收益率为4.69%，同比减少0.76个百分点；扣除非经常性损益后的加权平均净资产收益率同为4.69%，同比减少0.66个百分点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.